Risk factors for ESBL KPBSI | ESBL | Non-ESBL | Univariate analysis | Adjusted analysis (n = 271) | ||
---|---|---|---|---|---|---|
n/N (%) | n/N (%) | RRa (95 % CI) | p-value | RR (95 % CI) | p-value | |
Moderate or severe underweight for age | 209/339 (61.7) | 32/71 (45.1) | 1.13 (1.02–1.24) | 0.01 | 0.99 (0.97–1.01) | 0.40 |
HIV-infection | 79/249 (31.7) | 3/39 (7.7) | 1.22 (1.13–1.30) | <0.001 | 1.14 (1.04–1.25) | 0.01 |
Patient in the PICUb | 92/339 (27.1) | 11/71 (15.5) | 1.11 (1.02–1.21) | 0.04 | 0.99 (0.88–1.12) | 0.94 |
Cephalosporin exposure in the last 12 months pre-BSI | 184/339 (54.3) | 12/71 (16.9) | 1.30 (1.18–1.42) | <0.001 | 1.18 (1.06–1.31) | 0.002 |
Mechanical ventilation prior to BSI | 142/335 (42.4) | 13/71 (18.3) | 1.19 (1.10–1.29) | <0.001 | 1.08 (0.93–1.24) | 0.31 |
Continuous infusion for >3 days prior to BSI | 247/334 (74.0) | 30/71 (42.3) | 1.31 (1.16–1.49) | <0.001 | 1.15 (1.04–1.28) | 0.009 |
Indwelling urinary catheter prior to BSI | 139/335 (41.5) | 12/71 (16.9) | 1.20 (1.10–1.30) | <0.001 | 1.09 (0.99–1.20) | 0.10 |
Major surgical procedure prior to BSIc | 115/336 (34.2) | 16/71 (22.5) | 1.10 (1.01–1.20) | 0.04 | 1.06 (0.95–1.18) | 0.33 |
Skin erosions | 111/336 (33.0) | 19/71 (26.8) | 1.05 (0.96–1.15) | 0.30 | 1.07 (0.98–1.17) | 0.12 |
Previous KP infection within last 12 months | 39/338 (11.5) | 3/71 (4.2) | 1.14 (1.03–1.26) | 0.01 | 0.96 (0.84–1.11) | 0.62 |